How to map disease-specific changes using innovative LC-MS/MS-based omics approaches
Mass spectrometry coupled with liquid chromatography (LC-MS/MS) has become a cornerstone of clinical research for the analysis of biomarkers indicative of disease. The integration of this technology across omics applications provides significant advantages in terms of assay sensitivity, specificity, robustness, and multiplexing. These benefits are enabling researchers to gain new insights into disease etiology and pathogenesis through the identification and quantitation of disease-specific biomarkers.
In this webinar, Professor Martin Giera, Leiden University Medical Center and Professor Antonin Lamazière, Sorbonne University and Saint Antoine’s Hospital, will demonstrate how the latest advancements in mass spectrometry-based omics are providing a comprehensive assessment of disease mechanisms and patient-specific treatment responses.
The presentations will showcase several examples of how the integration of LC-MS/MS technology across omics applications provides disease state evaluation and monitoring, ultimately resulting in more personalized and effective patient care.
Key learning objectives
- Learn best practices for the development and implementation of LC-MS/MS-based omics assays for biomarker identification and quantitation
- Discover novel, LC-MS/MS-based metabolomic and lipidomic clinical applications that provide semiologic indications and understanding of disease pathogenesis
- Explore recent technological advancements in LC-MS/MS hardware and bioinformatics improving performance for biomarker discovery and quantitation
- Understand the benefits of sensitive MS techniques to establish mapping of changes in the human lipidome and metabolome linked to disease onset and progression
Who should attend?
- Anyone in a clinical laboratory interested in the development of LC-MS/MS-based clinical research, biomarker discovery, and assay development. Clinical researchers, healthcare professionals, biomarker discovery experts, laboratory directors, scientists, method/assay developers, and laboratory personnels who wish to learn about best practices for assay development and LC-MS/MS methods to accurately and reliability characterize, identify, and quantify biomarkers in clinical samples.
Certificate of attendance
- All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
- If you view the on-demand webinar, you can request a certificate of attendance by emailing [email protected].
Presenter: Martin Giera (Professor for Translational Metabolomics and Lipidomics , Leiden University Medical Center)
Martin Giera is a professor for translational metabolomics and lipidomics at the Leiden University Medical Center in the Netherlands. His research interests are focused on the role of metabolites and lipids in health and disease, including inflammatory diseases, cancer, and neurological disorders. The goal of his research is to identify specific metabolites and lipids associated with certain diseases that can be used to develop more accurate diagnoses and more effective treatment options for various disease states.
Presenter: Antonin Lamazière (Professor and hospital practitioner (Sorbonne University's Faculty of Medicine and Department Head Department of Clinical Metabolomics (Saint Antoine’s Hospital), Sorbonne University and Saint Antoine’s Hospital)
Antonin Lamazière is a professor and hospital practitioner at Sorbonne University's Faculty of Medicine. He heads the hospital department of Clinical Metabolomics at Hôpital Saint Antoine (AP-HP.Sorbonne Université). His research interests lie at the interface between metabolism, nutrition, and endocrine and metabolic pathologies. The goal of his research is to develop translational approaches based on more fundamental pathophysiological issues, leading to the development of new diagnostic tools for use in healthcare.
Moderator: Dora Wells (Clinical Content Editor, SelectScience)
